Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.

Key facts

Sponsor

Radboud University Medical Center

Intervention

Sentinel lymph node biopsy guided selective elective neck irradiation(radiation)

Enrollment

242 enrolled

Eligibility

18 years · All sexes

Timeline

2023 – 2029

Study locations (9)

• The Netherlands Cancer Institute, Amsterdam, Netherlands
• Radiotherapiegroep / Rijnstate Ziekenhuis, Arnhem, Netherlands
• Medisch Spectrum Twente (MST), Enschede, Netherlands
• University Medical Center Groningen, Groningen, Netherlands
• Leiden University Medical Center, Leiden, Netherlands
• MAASTRO Clinic / Maastricht University Medical Center, Maastricht, Netherlands
• Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
• Erasmus Medical Center, Rotterdam, Netherlands
• University Medical Center Utrecht, Utrecht, Netherlands

Collaborators

UMC Utrecht · The Netherlands Cancer Institute · Erasmus Medical Center · Leiden University Medical Center · Maastro Clinic, The Netherlands · Maastricht University Medical Center · University Medical Center Groningen · Radiotherapiegroep · Rijnstate Hospital · Medisch Spectrum Twente

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of the hypopharynx

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07063212
  A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
  Memorial Sloan Kettering Cancer Center
• RECRUITINGPHASE1NCT06761937
  Thermoradiotherapy for Locally Advanced Head and Neck Cancer Patients
  Erasmus Medical Center
• RECRUITINGPHASE3NCT06706401
  Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
  Centre Leon Berard
• RECRUITINGNCT06380686
  Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
  AIO-Studien-gGmbH
• RECRUITINGPHASE3NCT06525220
  A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
  Merus B.V.
• RECRUITINGPHASE2NCT04858269
  First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
  Wake Forest University Health Sciences
• ACTIVE NOT RECRUITINGPHASE3NCT04590963
  Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
  AstraZeneca
• RECRUITINGPHASE2, PHASE3NCT01810913
  Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
  National Cancer Institute (NCI)

See all trials for Squamous cell carcinoma of the hypopharynx →